Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.

To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved toward a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms "diabetes and kidney disease" and "diabetic kidney disease" are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria. Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD. World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the "Grading of Recommendations Assessment, Development and Evaluation" GRADE evidence profiles.

• Publication year

  2024

• Venue

  Nefrología

• Publication date

  2024-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nefro.2024.11.002PMID 40222774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

  2024cited by this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cited by this paper
• An integrated machine learning predictive scheme for longitudinal laboratory data to evaluate the factors determining renal function changes in patients with different chronic kidney disease stages

  2023cited by this paper
• Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease

  2023cited by this paper
• Kidney Function, Albuminuria and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis.

  2023cited by this paper
• Correlation Between the Variability of Different Obesity Indices and Diabetic Kidney Disease: A Retrospective Cohort Study Based on Populations in Taiwan

  2023cited by this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cited by this paper
• De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

  2023cited by this paper
• Population-Wide Screening for Chronic Kidney Disease

  2023cited by this paper
• Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

  2023cited by this paper
• Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease

  2023cited by this paper
• Development and validation of algorithms to identify patients with chronic kidney disease and related chronic diseases across the Northern Territory, Australia

  2022cited by this paper
• Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.

  2022cited by this paper
• European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack

  2022cited by this paper
• Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry

  2022cited by this paper
• OUP accepted manuscript

  2022cited by this paper
• Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

  2022cited by this paper
• Targeting inflammation to treat diabetic kidney disease: the road to 2030.

  2022cited by this paper
• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.

  2022cited by this paper
• KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

  2022cited by this paper
• Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).

  2022cited by this paper
• Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

  2022cited by this paper
• Trajectories of kidney function in diabetes: a clinicopathological update

  2021cited by this paper
• Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

  2021cited by this paper
• Platelet Abnormalities in Chronic Kidney Disease and Their Implications for Antiplatelet Therapy.

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

  2021cited by this paper
• Protein restriction for diabetic kidney disease.

  2021cited by this paper
• Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review

  2021cited by this paper
• Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients

  2021cited by this paper
• Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

  2021cited by this paper
• Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

  2021cited by this paper
• Optimizing Diet to Slow CKD Progression

  2021cited by this paper
• Kidney Biopsy in Type 2 Diabetic Patients: Critical Reflections on Present Indications and Diagnostic Alternatives

  2021cited by this paper
• Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?

  2021cited by this paper
• eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.

  2021cited by this paper
• Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

  2021cited by this paper
• Rivaroxaban in Peripheral Artery Disease after Revascularization.

  2020cited by this paper
• Risk factors for non-diabetic renal disease in diabetic patients

  2020cited by this paper
• Potential biomarkers for early detection of diabetic kidney disease.

  2020cited by this paper
• SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review

  2020cited by this paper
• Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.

  2020cited by this paper
• European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis.

  2020cited by this paper
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).

  2020cited by this paper
• Polypill with or without Aspirin in Persons without Cardiovascular Disease.

  2020cited by this paper
• A comparative study of efficacy of enalapril versus telmisartan in patients with diabetic nephropathy

  2020cited by this paper
• Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

  2020cited by this paper
• Optimizing the timing of nephrology referral for patients with diabetic kidney disease

  2020cited by this paper
• Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society.

  2020cited by this paper
• Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

  2020cited by this paper
• International consensus definitions of clinical trial outcomes for kidney failure: 2020.

  2020cited by this paper
• Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.

  2020cited by this paper
• Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease

  2020cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2019cited by this paper
• Robust clinical marker identification for diabetic kidney disease with ensemble feature selection

  2019cited by this paper
• Evaluation of Serum microRNAs in Patients with Diabetic Kidney Disease: A Nested Case-Controlled Study and Bioinformatics Analysis

  2019cited by this paper
• Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

  2019cited by this paper
• Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

  2019cited by this paper
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

  2019cited by this paper
• Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

  2019cited by this paper
• Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.

  2019cited by this paper
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

  2019cited by this paper
• Ticagrelor in Patients with Stable Coronary Disease and Diabetes.

  2019cited by this paper
• Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.

  2019cited by this paper
• Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2019cited by this paper
• Novel Biomarkers for Change in Renal Function in People With Dysglycemia

  2019cited by this paper
• Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance

  2019cited by this paper
• The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening

  2019cited by this paper
• Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.

  2018cited by this paper
• Identification of Novel Urinary Biomarkers for Predicting Renal Prognosis in Patients With Type 2 Diabetes by Glycan Profiling in a Multicenter Prospective Cohort Study: U-CARE Study 1

  2018cited by this paper
• Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: a cross-sectional study

  2018cited by this paper
• Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.

  2018cited by this paper
• Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

  2018cited by this paper
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

  2018cited by this paper
• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

  2018cited by this paper
• Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.

  2018cited by this paper
• Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study

  2018cited by this paper
• Low protein diets for non-diabetic adults with chronic kidney disease.

  2018cited by this paper
• Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: Results of the REMOTEV registry.

  2018cited by this paper
• Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

  2018cited by this paper
• Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry.

  2017cited by this paper
• Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes

  2017cited by this paper
• Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study‐level meta‐analysis of phase III randomized trials

  2017cited by this paper
• Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

  2017cited by this paper
• The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

  2017cited by this paper
• Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

  2017cited by this paper
• Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes

  2017cited by this paper
• Dietary Approaches in the Management of Diabetic Patients with Kidney Disease

  2017cited by this paper
• Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries

  2017cited by this paper
• A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

  2016cited by this paper
• Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.

  2016cited by this paper
• Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes

  2016cited by this paper
• Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications

  2016cited by this paper

• Benefit of lipid control in chronic disease and diabetes: Beyond statins.

  2026cites this paper
• [SEMERGEN position paper on chronic kidney disease].

  2026cites this paper
• Undiagnosed chronic kidney disease in people with type 2 diabetes in Spain: Prevalence, treatment patterns and associated factors in a multicentre cross-sectional study.

  2026cites this paper
• Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitus.

  2025cites this paper
• Bridging gaps in chronic kidney disease management: insights from clinicians on real-world practices

  2025cites this paper
• Recommendations for the evaluation and treatment of patients with diabetes and albuminuria. Role of non-steroidal mineralocorticoid antagonism.

  2025influential citation
• Diabetic Nephropathy Nomogram Construction Based on Optical Coherence Tomography Angiography Variables.

  2025cites this paper
• Chronic kidney disease screening in primary care: a descriptive analysis of the Girona Sud health region

  2025cites this paper
• Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed

  2025cites this paper
• Remnant cholesterol for diabetic kidney disease risk stratification in type 2 diabetes: a machine learning-based prevention tool

  2025cites this paper
• Machine learning-based prediction of tubulointerstitial lesions in diabetic kidney disease: a multicenter validation study

  2025cites this paper
• Comprehensive management of chronic kidney disease in the old population

  2025cites this paper